From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer
Jiangang Sun,Xiaojing Li,Peng Chen,Yongshun Gao
DOI: https://doi.org/10.2147/JIR.S368138
IF: 4.5
2022-07-16
Journal of Inflammation Research
Abstract:Jiangang Sun, 1, &ast Xiaojing Li, 2, &ast Peng Chen, 1 Yongshun Gao 1 1 Department of Gastrointestinal Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People's Republic of China; 2 Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People's Republic of China &astThese authors contributed equally to this work Correspondence: Peng Chen; Yongshun Gao, Department of Gastrointestinal Surgery, the First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, Henan, 450052, People's Republic of China, Email ; Current Therapeutic modalities provide no survival advantage to gastric cancer (GC) patients. Targeting the human epidermal growth factor receptor-2 (HER-2) is a viable therapeutic strategy against advanced HER-2 positive GC. Antibody-drug conjugates, small-molecule tyrosine kinase inhibitors (TKIs), and bispecific antibodies are emerging as novel drug forms that may abrogate the resistance to HER-2-specific drugs and monoclonal antibodies. Chimeric antigen receptor-modified T cells (CAR-T) targeting HER-2 have shown considerable therapeutic potential in GC and other solid tumors. However, due to the high heterogeneity along with the complex tumor microenvironment (TME) of GC that often leads to immune escape, the immunological treatment of GC still faces many challenges. Here, we reviewed and discussed the current progress in the research of anti-HER-2-CAR-T cell immunotherapy against GC. Keywords: CAR-T, HER-2, gastric cancer, immunotherapy, target Gastric cancer (GC) ranks fifth in incidence and fourth in mortality among all malignancies worldwide, which was equal to more than 1 million new cases and 769 thousand deaths in 2020. 1 Given the considerable tumor heterogeneity, the five-year survival rate of advanced GC is reported to be less than 30%. 2,3 At present, the treatment of GC mainly includes surgical resection, 4,5 chemotherapy, 6,7 traditional Chinese medicine (TCM) therapy, 8 targeted therapy 9,10 and immunotherapy 11,12 (Figure 1). Figure 1 Treatment strategies for gastric cancer. Surgical resection, chemotherapy, traditional Chinese medicine, targeted therapy and immunotherapy. Based on the results of CLASS01 13 and CLASS02 14 clinical trials, laparoscopic total gastrectomy is a potentially safe alternative to open total gastrectomy for both advanced and early stage (I) GC patients. Recent studies have also reported high efficacy and low toxicity of TCM-based treatment of GC, 8 although the molecular mechanisms are still unclear. Furthermore, perioperative chemotherapy for GC has reached a consensus based on the results of CLASSIC, MAGIC, RESOLVE and other randomized controlled trials conducted over the past decade. 15 Despite advances in the molecular typing of GC and the development of targeted and immunogenic drugs, their clinical applications remain limited, 16 especially for the human epidermal growth factor receptor type 2 (HER-2) positive, 17 microsatellite instability-high 18 and Epstein–Barr virus-associated 19 subtypes. Moreover, studies have increasingly shown that conventional chemotherapy is not the optimum choice for perioperative treatment, and the outcomes of the patients depend significantly on the specific tumor stage and mutation status. HER-2 is a member of the epidermal growth factor receptor (EGFR) family, 20 and is overexpressed in many solid tumors including breast cancer (BC), stomach cancer, colon cancer and ovarian cancer. 21,22 The Phase 3 ToGA trial established trastuzumab as a first-line treatment for advanced HER-2 positive GC. 23 However, lapatinib, trastuzumab emtansine (T-DM1) and pertuzumab have not shown encouraging results after first-line treatment progression. 24 Immunotherapy and targeted therapy are now indispensable for GC treatment. The development of immune inhibitors against advanced GC cells has been one of the most significant improvements in recent years. 25 Chimeric antigen receptor T cell therapy (CAR-T) is a promising treatment strategy against cancers. 26 Two CAR-T cell-based therapies have been approved by the Food and Drug Administration (FDA) to treat refractory leukemia and lymphoma. 27 However, the efficacy of CAR-T cells against sarcomas and other solid tumors is limited due to the immunosuppressive tumor microenvironment (TME). 28,29 Compared to conventional therapies, CAR-T cells can directly recognize antigens on the surface of tumor cells and kill tumor cells, the -Abstract Truncated-
immunology